0001127602-24-012710.txt : 20240409 0001127602-24-012710.hdr.sgml : 20240409 20240409162525 ACCESSION NUMBER: 0001127602-24-012710 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Deschatelets Pascal CENTRAL INDEX KEY: 0001657720 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 24833042 MAIL ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-04-08 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001657720 Deschatelets Pascal C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Scientific Officer 1 Common Stock 2024-04-08 4 M 0 69107 3.76 A 1185090 D Common Stock 2024-04-08 4 S 0 64379 54.1165 D 1120711 D Common Stock 2024-04-08 4 S 0 4728 54.9152 D 1115983 D Stock Option (Right to Buy) 3.76 2024-04-08 4 M 0 69107 0 D 2026-02-07 Common Stock 69107 37280 D This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This transaction was executed in multiple trades at prices ranging from $53.770 - $54.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $54.775 - $55.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This stock option was granted on 02/08/2016 and is fully vested. /s/ David Watson, attorney-in-fact for Pascal Deschatelets 2024-04-09